Astatine

ACL Airshop Appoints Bernhard Kindelbacher as Chief Executive Officer

Retrieved on: 
Monday, February 5, 2024
AIP, Multimedia, Growth, Senior, Projection, Townes, ACL, University, ANA, Cathay Pacific, Transport, ULD, Lufthansa Cargo, Air cargo, Atmosphere, Investment, MBA, Vice, Education, Lufthansa, Astatine, Business, Management

GREENVILLE, S.C. and AMSTERDAM, Feb. 5, 2024 /PRNewswire/ -- ACL Airshop , a global leader in air cargo Unit Load Device (ULD) logistics solutions to over 200 airlines, air cargo carriers, and other transportation clients, announces the appointment of Bernhard Kindelbacher as Chief Executive Officer, with an effective date of March 1, 2024.

Key Points: 
  • GREENVILLE, S.C. and AMSTERDAM, Feb. 5, 2024 /PRNewswire/ -- ACL Airshop , a global leader in air cargo Unit Load Device (ULD) logistics solutions to over 200 airlines, air cargo carriers, and other transportation clients, announces the appointment of Bernhard Kindelbacher as Chief Executive Officer, with an effective date of March 1, 2024.
  • Bernard Kindelbacher, new CEO for ACL Airshop, is a senior veteran of the Air Cargo industry, with global experience.
  • Kindelbacher said: "ACL Airshop is a successful worldwide entrepreneurial team of air cargo and logistics experts with a strong High-Performance Culture.
  • Townes, reflecting on the progress of ACL Airshop , said: "Bernhard is the right leader for this next chapter of ACL Airshop, with deep professional roots and impeccable expertise in the global air cargo sector."

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

Retrieved on: 
Wednesday, March 8, 2023
Radiology, Professional Services, Pharmaceutical, Oncology, Start-Up, Medical Devices, University, Other Manufacturing, Education, Clinical Trials, Manufacturing, Health, Acceleration, Nuclear medicine, Nature, Japan Science and Technology Agency, Ris, Kita, Radiopharmaceutical, Targeted alpha-particle therapy, TAT, Research, Thyroid cancer, Technology Agency of the Czech Republic, Bismuth, OPERA, RI, SHI, Drug discovery, JST, Fukushima Medical University, Multimedia, Halogen, AF, Isotope, Osaka University, Mission, Head, Pharmaceutical industry, Atomic, Astatine

Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).

Key Points: 
  • Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
  • View the full release here: https://www.businesswire.com/news/home/20230308005372/en/
    Image Diagram of TAT (Graphic: Business Wire)
    AF will aim at establishing their pipeline (*1).
  • Development of their radiopharmaceuticals is expected to be progressed by this funding and will lead more needs of Astatine-211.
  • Astatine-211 (211At, Atomic number 85, Half life time 7.2H) is an element belonging to halogens and has the property of emitting alpha particle.

Consolidated Communications Closes on Sale of its Kansas City Assets

Retrieved on: 
Thursday, December 1, 2022
Telecommunications, Networks, Other Communications, Internet, Communications, Technology, VoIP, Other Technology, COVID-19, Consolidated Communications, Partner, Communication, Cyberattack, CNSL, Partnership, Legislation, Searchlight Capital, Consolidated, Security (finance), Astatine, Sale, Telecommunication, Failure, Form, Coronavirus, Form 10-K, Person, Bank, Kansas City metropolitan area

Were pleased to have closed on the Kansas asset sale which results in a greater focus on our core regions as we utilize the proceeds to support our fiber expansion plans, said Bob Udell, president and chief executive officer of Consolidated Communications.

Key Points: 
  • Were pleased to have closed on the Kansas asset sale which results in a greater focus on our core regions as we utilize the proceeds to support our fiber expansion plans, said Bob Udell, president and chief executive officer of Consolidated Communications.
  • Consolidateds Kansas City operations are estimated to contribute approximately $45 million of revenue in the full year 2022.
  • The Kansas City operations includes services to residential and commercial customers.
  • Bank Street Group LLC served as the exclusive financial advisor to Consolidated Communications on the transaction.

Global Alpha Emitters Market to Grow by 35.82% Annually Through 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Health, Oncology, Medical applications of radio frequency, Region, Cancer, Prevalence, CAGR, USD, Growth, Lymphoma, Melanoma, Asphalt, Vaccine, Platinum, Bismuth, Astatine

The "Alpha Emitters Market Analysis, By Radionuclide Type (Bismuth, Astatine, Radium), By Medical Application, By End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alpha Emitters Market Analysis, By Radionuclide Type (Bismuth, Astatine, Radium), By Medical Application, By End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The alpha emitters market size is estimated to be USD 698.3 million in 2021 and is expected to witness a CAGR of 35.82% during the forecast period 2022-2029.
  • The increased public knowledge of the potential advantages of targeted alpha emitters and the prevalence of several malignancies, including ovarian, pancreatic, lymphoma, and melanoma are factors contributing to the market growth.
  • However, stringent regulatory requirement is expected to hinder the growth.

Medolife Rx Announces Successful Stability Results on Escozine Conjugated With Radioactive Iodine

Retrieved on: 
Thursday, July 1, 2021
Physical sciences, Chemistry, Chemical elements, Halogens, Oxidizing agents, Iodine, Radioactive decay, Astatine

Conjugation of Escozine with radioactive iodine allows for researchers to more clearly see where and how Escozine is absorbed and processed in the body.

Key Points: 
  • Conjugation of Escozine with radioactive iodine allows for researchers to more clearly see where and how Escozine is absorbed and processed in the body.
  • Many APIs do not remain stable when conjugated with radioactive iodine, eliminating the possibility of certain types of PK studies.
  • However, through this preclinical study, Medolife has proven the stability of Escozine paired with radioactive iodine and is prepared to move into a full PK study per the guidelines given by the FDA.
  • Beyond our successful stability result on Escozines peptide conjugated with radioactive iodine, we were even more excited by its potential applications in the field of diagnostics, said Medolife CEO Dr. Arthur Mikaelian.

ARTMS Inc. produces Ga-68 in US Commercial Nuclear Pharmacy using ARTMS Solid Target Technology

Retrieved on: 
Tuesday, May 25, 2021
Health, Medical devices, Logistics, Supply chain management, Transport, Research, Science, Pharmaceutical, Physical sciences, Natural sciences, Chemistry, Medical physics, Pharmacy, Nuclear medicine, Chemical elements, Nuclear pharmacy, Quantm, Astatine

ARTMS Inc. (ARTMS) is pleased to announce the production of Ga-68 Chloride using a medical cyclotron in a US based commercial nuclear pharmacy.

Key Points: 
  • ARTMS Inc. (ARTMS) is pleased to announce the production of Ga-68 Chloride using a medical cyclotron in a US based commercial nuclear pharmacy.
  • ARTMS Quantm Irradiation System will enable commercial nuclear pharmacies to meet the growing demand for Ga-68 based products.
  • ARTMS is also engaged in discussions with the FDA Division of Drug Shortages on how ARTMS can solve the projected Ga-68 shortage in the United States.
  • ARTMS has a variety of solid targets commercially available used in combination with ARTMS QUANTM Irradiation System (QIS).

Additional Pathfinder Element Data Refines Anomaly Trend on Pakwash Fault on Kwai Property, Red Lake, Ontario

Retrieved on: 
Tuesday, December 22, 2020
Chemistry, Physical sciences, Chemical elements, Native element minerals, Metalloids, Anions, Telluride, Tellurium, Bismuth, Gold, Astatine

Additional data is still being generated from three holes on the south trend of IP anomalies and a parallel fault structure to the south.

Key Points: 
  • Additional data is still being generated from three holes on the south trend of IP anomalies and a parallel fault structure to the south.
  • The four South Trend holes are in the most southwest part of the property.
  • Silver values are also dispersed along the fault and Bismuth is associated with the tellurium, which is a common occurrence in tellurides near gold deposits.
  • The Company is focused on exploring and developing the gold and silver potential of properties in the Red Lake District of Ontario.

Global Bismuth Nitrate Market Analysis & Demand Forecast Report 2020-2030 by Grade (Pharmaceutical Grade, Industrial Grade), & Application (Drug Formulation, Chemical Manufacturing) - ResearchAndMarkets.com

Retrieved on: 
Monday, November 16, 2020
Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Natural sciences, Chemical elements, Bismuth, Pnictogens, Pharmaceutical industry, Astatine, Medication

The "Bismuth Nitrate Market Research Report: By Grade (Pharmaceutical Grade, Industrial Grade), Application (Drug Formulation, Chemical Manufacturing) - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bismuth Nitrate Market Research Report: By Grade (Pharmaceutical Grade, Industrial Grade), Application (Drug Formulation, Chemical Manufacturing) - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • In terms of application, the bismuth nitrate market is categorized into chemical manufacturing, drug formulation, and others.
  • On the basis of grade, the bismuth nitrate market is divided into, industrial grade, pharmaceutical grade, and others.
  • Furthermore, the growing number of cancer patients in the APAC region is also driving the demand for bismuth nitrate.

ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

Retrieved on: 
Wednesday, May 6, 2020
Physical sciences, Chemistry, Chemical elements, Einsteinium, Astatine, Prostate cancer, Nuclear medicine, Cyclotron, Polonium, Radium

ARTMS flagship product, the QUANTM Irradiation System(QIS) provides cost-effective, decentralized, local production of important medical isotopes, including 68Ga.

Key Points: 
  • ARTMS flagship product, the QUANTM Irradiation System(QIS) provides cost-effective, decentralized, local production of important medical isotopes, including 68Ga.
  • ARTMS has recently presented data demonstrating industry leading multi-curie production of 68Ga following less than two hours of cyclotron irradiation time.
  • As part of the collaboration, ARTMS will also provide technical personnel to assist with Zinc-68 (68Zn) solid target irradiations and will utilize its intellectual property for high activity 68Ga processing.
  • We are proud to join forces with Telix to satisfy their supply need for high-value radiopharmaceuticals for detection of prostate cancer.

ioTech International to Protect Healthcare Workers from COVID-19 Exposure with Molecular iodine in Controlled Study

Retrieved on: 
Tuesday, May 5, 2020
Chemistry, Physical sciences, Chemical elements, Halogens, Oxidizing agents, Iodine, Coronaviridae, Middle East respiratory syndrome-related coronavirus, Coronavirus, Astatine, Bromine, Iodine deficiency

Each of these unique, high performance products utilize ioTech's patented molecular iodine technology.

Key Points: 
  • Each of these unique, high performance products utilize ioTech's patented molecular iodine technology.
  • The endpoint of the six-week study will be a reduction in COVID-19 symptoms from healthcare workers who are using the ioTech products and are treating novel coronavirus patients compared to the control group.
  • ioTech International is a world leader in molecular iodine research and development.
  • Each high-performance, unique product features ioTech's breakthrough, antimicrobial molecular iodine technology.ioTech International products can be found at iotechinternational.com.